<p>Shares of Pfizer Ltd rose nearly 4 per cent in early trade on Thursday after Pfizer Inc announced that the Covid-19 vaccine developed in partnership with BioNTech was found 95 per cent effective in the final analysis of the Phase 3 trial.</p>.<p>The stock surged by 3.83 per cent to Rs 5,098 on the BSE.</p>.<p>Similarly, on NSE, shares of Pfizer Ltd rose by 3.85 per cent to Rs 5,096.20.</p>.<p>Global drugmakers Pfizer and BioNTech said on Wednesday that their COVID-19 vaccine was found 95 per cent effective in the final analysis of the Phase 3 trial, including in people aged over 65 years, paving the way for the companies to apply for emergency authorisation from US regulators within days.</p>.<p>Further, Pfizer and BioNTech said they have concluded a phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy endpoints.</p>.<p>Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.</p>
<p>Shares of Pfizer Ltd rose nearly 4 per cent in early trade on Thursday after Pfizer Inc announced that the Covid-19 vaccine developed in partnership with BioNTech was found 95 per cent effective in the final analysis of the Phase 3 trial.</p>.<p>The stock surged by 3.83 per cent to Rs 5,098 on the BSE.</p>.<p>Similarly, on NSE, shares of Pfizer Ltd rose by 3.85 per cent to Rs 5,096.20.</p>.<p>Global drugmakers Pfizer and BioNTech said on Wednesday that their COVID-19 vaccine was found 95 per cent effective in the final analysis of the Phase 3 trial, including in people aged over 65 years, paving the way for the companies to apply for emergency authorisation from US regulators within days.</p>.<p>Further, Pfizer and BioNTech said they have concluded a phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy endpoints.</p>.<p>Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.</p>